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Abstract
Mutations are at the root of many human diseases. Still, we
largely do not exactly understand how they trigger pathogen-
esis. One, more recent, hypothesis has been that they
comprehensively perturb protein–protein interaction (PPI)
networks and significantly alter key biological processes.
Under this premise, many rare genetic disorders with Men-
delian inheritance, like Huntington’s disease and several
spinocerebellar ataxias, are likely to be caused by complex
genotype–phenotype relationships involving abnormal PPIs.
These altered PPI networks and their effects on cellular
pathways are poorly understood at the molecular level. In this
review, we focus on PPIs that are perturbed by the expanded
pathogenic polyglutamine tract in huntingtin (HTT), the protein
which, in its mutated form, leads to the autosomal dominant,
neurodegenerative Huntington’s disease. One aspect of
perturbed mutant HTT interactions is the formation of
abnormal protein species such as fibrils or large neuronal
inclusions as a result of homotypic and heterotypic aberrant
molecular interactions. This review focuses on abnormal
PPIs that are associated with the assembly of mutant HTT
aggregates in cells and their potential relevance in disease.
Furthermore, the mechanisms and pathobiological processes
that may contribute to phenotype development, neuronal
dysfunction and toxicity in Huntington’s disease brains are
also discussed.
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Abnormal interactions are commonly found in
genetic diseases including Huntington’s disease
Proteins in cells do not function in isolation. Rather, they
form either stable or transient protein assemblies to perform
their cellular tasks (Gromiha et al. 2017; Ivarsson and Jemth
2018). Therefore, the detection and functional characteriza-
tion of protein–protein interactions (PPIs) is of critical
importance to gain a better understanding of cellular
processes and disease phenotypes.
A large number of rare genetic disorders with Mendelian
inheritance have been identified (Pogue et al. 2018;
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Abbreviations used: 26S, cytosolic 26S proteasome; CAG, trinu-
cleotide; CBP, CREB-binding protein; cryo-EM, cryo-electron micro-
scopy; CSE, cystathione c-lyase; DHHC17, palmitoyltransferase; DRP1,
dynamin-related protein-1; FUS, fused in sarcoma; GABA, gamma-
aminobutyric acid; HAP1, huntingtin-associated protein 1; HD, Hunting-
ton's disease; HEAT, acronym for four proteins – huntingtin, elongation
factor 3 (EF3), protein phosphatase 2A (PP2A) and the yeast kinase
TOR1; HIP14, huntingtin interacting protein 14; HIP14L, HIP14-related
protein; HTT, huntingtin; LCRs, low complexity regions; mHTT, mutant
huntingtin; mHTTex1, mutant huntingtin exon-1 protein; mRNA, mes-
senger RNA; MS, mass spectrometry; mTOR, mechanistic target of
rapamycin; N17, 17 N-terminal HTT amino acids; N2a, mouse neurob-
lastoma cell line; NeuroD, neurogenic differentiation factor 1; NIIs,
neuronal intranuclear inclusions; NRSF, neuron-restrictive silencer factor;
PC12, rat pheochromocytoma cell line; polyQ, polyglutamine; PPI,
protein–protein interaction; PRD, proline rich domain; REST, RE1-
silencing transcription factor; Rhes, RAS-like mTOR inducer; RNA,
ribonucleic acid; SNAP-25, synaptosomal nerve-associated protein 25;
SP1, specificity protein 1; TBP, TATA-binding protein; TFIID, transcrip-
tion factor II D; TFIIF, transcription factor II F; UPS, ubiquitin-
proteasome system; VCP, valosin-containing protein; wtHTT, wild-type
huntingtin; zQ175, knock-in mice expressing full-length mHTT.
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Amberger et al. 2019). These diseases are generally caused
by single mutations (missense point mutations or in-frame
insertions or deletions, e.g.) located in specific genes that
drive the pathogenic process (Fig. 1) and lead to the
development of distinct phenotypes (Chen et al. 2018). This
suggests that simple, linear genotype-to-phenotype relation-
ships underlie the development of rare genetic diseases and
that therapeutic strategies should be straightforward. How-
ever, experimental evidence increasingly points to complex
genotype–phenotype relationships (Barabasi et al. 2011).
This is easily explained: genetic mutations lead to the
production of deviant proteins that are in direct contact with
various other proteins in cells. A mutation in a single protein
can therefore perturb the interactions of many associated
proteins and their specific biological functions, and in this way
cause disease (Fig. 1). Thus, it seems reasonable to regard the
phenotypes of rare genetic diseases as perturbations of
complex cellular networks rather than the result of the
alteration in a single disease protein. Recent systematic
profiling of human disease–protein interaction networks
indicates that ~ 60% of previously identified disease-associ-
ated missense mutations perturb PPIs (Sahni et al. 2015). This
means that the interaction network or ‘edgotype’ of a specific
mutation represents the fundamental relationship between a
specific genotype and a disease phenotype (Sahni et al. 2013).
Huntington’s disease (HD) is a rare genetic neurodegen-
erative disorder that is caused by a trinucleotide (CAG)
triplet repeat expansion located in exon-1 in the huntingtin
(HTT) gene (Bates et al. 2015). A CAG sequence with 40 or
more CAG repeats leads to HD, whereas the CAG sequence
is repeated between 9 and 35 times in healthy individuals.
This mutation results in the synthesis of an HTT protein with
an elongated polyglutamine (polyQ) tract in neurons and
various other cells (Saudou and Humbert 2016). This
suggests that an abnormal polyQ expansion located at the
N-terminus of HTT drives pathogenesis (Harjes and Wanker
2003). HTT is a large protein of ~ 350 kDa that plays critical
functional roles in gene expression regulation (Valor 2015),
vesicle transport (Harjes and Wanker 2003) and autophagy
(Ochaba et al. 2014). It is modified post-translationally at
multiple sites (Cariulo et al. 2017; Harding et al. 2019) and
gets cleaved by various proteases (Sanchez Mejia and
Friedlander 2001), leading to the release of N-terminal
fragments with an expanded polyQ sequence, which have a
high propensity to misfold and self-assemble into fibrillar
aggregates (Scherzinger et al. 1997; Trepte et al. 2014). As a
consequence, intranuclear inclusions are formed in neurons.
They consist of aggregates of mutant HTT fragments as well
as a variety of further proteins like ubiquitin, chaperones, and
components of the ubiquitin-proteasome system (DiFiglia
et al. 1997; Waelter et al. 2001) and are a pathological
hallmark of HD (Fig. 2).
To date, more than 400 HTT associated proteins have been
identified using biochemical and genetic PPI-detection
methods (Shirasaki et al. 2012; Langfelder et al. 2016;
Alanis-Lobato et al. 2017). These include proteins that
function in gene regulation, RNA splicing, vesicle transport
and protein degradation (Harjes and Wanker 2003; Saudou
and Humbert 2016), supporting a functional role of the wild-
type HTT (wtHTT) or its fragments in these processes. A
substantial number of studies have provided experimental
evidence that the expanded polyQ sequence in HTT perturbs
PPIs in mammalian cells. Here, we aim to focus specifically
on interactions of mutant HTT (mHTT) that may be
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Fig. 1 Genetic mutations perturb protein–protein interaction networks. (a) The Human Gene Mutation Database currently lists more than 170 000
mutations of different types occurring in the human genome. (b) A fraction of these perturb protein–protein interaction networks and can lead to a
gain or loss of interactions in cells. These changes manifest as different disease phenotypes.
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perturbed in the human disease and discuss their putative
impact on cellular processes and phenotypic changes in
model systems.
Various putatively pathogenic mHTT protein
species have been described
Besides full-length mHTT with a pathogenic polyQ tract and
a largely a-helical conformation (Guo et al. 2018), a variety
of other conformationally distinct mHTT protein species
have been reported to be present in HD patient brains and
disease models (Scherzinger et al. 1997; DiFiglia et al. 1997;
Sathasivam et al. 2010). This includes monomers and
oligomers of full-length mHTT (Sathasivam et al. 2010;
Shirendeb et al. 2011) as well as protein species that are
formed of truncated N-terminal mHTT fragments, such as
oligomers or b-sheet-rich, ordered fibrils (Wagner et al.
2018). Several lines of evidence indicate efficient proteolytic
cleavage of full-length mHTT resulting in the release of N-
terminal polyQ-containing fragments (Lunkes et al. 2002;
Landles et al. 2010). Furthermore, a truncated mutant HTT
exon-1 (mHTTex1) fragment is continuously produced by
messenger RNA splicing in addition to the full-length protein
(Sathasivam et al. 2013; Neueder et al. 2018). It is important
to note that monomeric, oligomeric and fibrillar forms of
mHTT are dynamic structures that can interconvert into each
other in vitro and in vivo (Hoffner and Djian 2014; Sahoo
et al. 2016) and eventually are deposited into large inclusion
bodies in cells (Waelter et al. 2001). A schematic represen-
tation of previously described, potentially pathogenic mHTT
protein species and their assembly into inclusion bodies is
shown in Fig. 2.
Recently, a high-resolution cryo-electron microscopy
(cryo-EM) structure was obtained for soluble full-length
wtHTT in complex with its interaction partner HAP40 (Guo
et al. 2018). It revealed that wtHTT is predominantly a
folded, a-helical protein that consists of three major
domains. Two large domains containing multiple HEAT
repeats (N-HEAT and C-HEAT) located at the N- and C-
terminus of wtHTT are connected by a smaller bridge
domain. The full-length protein is conformationally flexible
and is stabilized upon binding to its interacting partner
protein. The structural studies also support the view that
full-length wtHTT is a multivalent hub that interacts with
many different proteins in mammalian cells (Harjes and
Wanker 2003; Li and Li 2004). Interestingly, no high-
resolution secondary structure was obtained by cryo-EM for
the N-terminal polyQ tract. This suggests that this region is
highly flexible and likely to have limited influence on the
overall a-helical architecture of full-length wtHTT (Fig. 2).
Biochemical and biophysical studies with pathogenic and
non-pathogenic full-length HTT proteins have shown that
expanded polyQ tracts can increase the a-helical properties
of HTT and alter the intramolecular interactions between N-
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Fig. 2 Schematic representation of different mutant huntingtin species
along the aggregation cascade. Each of these species can be
expected to have different interactors and might therefore have
different pathobiological roles in the disease.
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and C-terminal domains (Vijayvargia et al. 2016). Thus, it
may be appropriate to describe wtHTT and mutant HTT as,
at least in part, structurally distinct proteins, which may
have important differences in their interaction profiles in
mammalian cells.
Apart from full-length mHTT, truncated N-terminal
polyQ-containing fragments may also play a critical role in
HD (Davies et al. 1997; Ast et al. 2018). The mHTTex1
fragment has been reported to efficiently self-assemble into
higher order structures such as spherical oligomers or
amyloid fibrils in vitro and in vivo (Sathasivam et al. 2010;
Sahoo et al. 2016; Wagner et al. 2018). It has been proposed
that such protein assemblies might drive HD pathogenesis
(Wanker 2000). Whether oligomers, fibrils or even misfolded
mHTT monomers are the major proteotoxic species, how-
ever, is still a matter of debate (Diaz-Hernandez et al. 2005;
Sahl et al. 2012; Leitman et al. 2013). Recent studies from
different laboratories demonstrated that polyQ-expanded
mHTTex1 fibrils, rather than oligomers or misfolded
monomers exert toxicity in HD (Drombosky et al. 2018).
Minute amounts of small self-propagating HTTex1Q97
fibrils in neurons were shown to be sufficient to dramatically
shorten the life-span of HD transgenic flies (Ast et al. 2018).
Here, it is important to note that misfolded mHTTex1
monomers and oligomers are structurally distinct from
amyloid fibrils. While monomers and oligomers are dynamic
structures and are assumed to have random coil or a-helical
conformation in vivo (Kang et al. 2017a; Kotler et al. 2019),
fibrillar mHTTex1 assemblies are rigid and predominantly
consist of stable b-sheets (Hoop et al. 2016; Lin et al. 2017).
Antibody binding studies demonstrated that polyQ tracts are
exposed on the surface of mHTTex1 monomers and
oligomers, but not on the surface of amyloid fibrils (Wagner
et al. 2018). Being structurally and morphologically distinct,
mHTT fibrils may have very different biological properties
and interaction profiles in mammalian cells from those of
non-b-sheet mHTT species.
Abnormal interactions between full-length mHTT
and cellular proteins
Axonal transport
Previous studies have shown that a protein complex
consisting of full-length HTT and its interaction partner
huntingtin-associated protein 1 (HAP1) regulates the trans-
port of organelles and various types of membrane vesicles
along axons (Fig. 3), in both anterograde and retrograde
directions (Gauthier et al. 2004; Wong and Holzbaur 2014).
This happens because the HTT-HAP1 protein complex binds
to molecular motors and to cargo vesicles such as synaptic
precursor vesicles (Zala et al. 2013) or autophagosomes
(Wong and Holzbaur 2014). The expression of full-length
mHTT was shown to perturb the trafficking of vesicles with
GABAA receptors to synapses with effects on
neurotransmission, supporting a functional role of the
HTT-HAP1 complex in the anterograde transport of mem-
brane vesicles (Twelvetrees et al. 2010). In the same study,
HAP1 stably associated with KIF5 motors, a critical
interaction for the transport of GABAA receptors to synapses.
HAP1 interacts more strongly with mutant than wtHTT in
yeast two-hybrid assays (Li et al. 1995), suggesting that the
expanded polyQ in full-length mHTT may also abnormally
stabilize this interaction in neurons. This enhanced binding
may in turn perturb the functionally important interaction
between HAP1 and KIF5 motors, leading to a decrease in
GABAA-receptor trafficking in neurons. The transport of
GABAA receptors to synapses is critical to brain excitability,
and a significant reduction in their abundance in synapses
may contribute to the development of HD (Garret et al.
2018).
Autophagosomes are known to form constitutively at
axon tips and undergo robust retrograde axonal transport
towards the cell body (Maday and Holzbaur 2012). Recent
findings indicate that full-length wtHTT and its adaptor
protein HAP1 control the retrograde transport of
autophagosomes in neurons (Wong and Holzbaur 2014).
Strikingly, the movement of autophagosomes to cell bodies
was significantly impaired upon the expression of full-
length mHTT in neurons (Fig. 3), leading to an accumu-
lation of these structures with undegraded mitochondrial
cargo in axons (Wong and Holzbaur 2014). Thus, an
abnormal stabilization of the mHTT-HAP1 interaction
through the expanded polyQ tract may disrupt autophago-
some transport and lead to inefficient clearance of mito-
chondrial fragments in neurons. This, in turn, may
contribute to neuronal dysfunction and cell death observed
in HD patient brains.
Autophagy
Initial investigations have demonstrated that the activity of
macroautophagy is significantly reduced in cells of HD
patients compared to healthy controls, with a cargo-
recognition failure likely to be responsible (Martinez-
Vicente et al. 2010). More recent investigations in mam-
malian cells showed full-length wtHTT to interact directly
with proteins that play a key role in selective autophagy, for
example, ULK1, p62 and GABARAPL1 (Ochaba et al.
2014; Rui et al. 2015) and play a key role in the cargo
recruitment process in cells (Bjorkoy et al. 2006). ULK1 is
an autophagy-activating kinase that forms a complex with
the cargo receptor p62, which recognizes polyubiquitin
chains attached to protein aggregates (Rui et al. 2015). It is
currently believed that, through the formation of a stable
HTT-ULK1-p62 protein complex, misfolded, ubiquitinated
protein aggregates are recognized in cells and subsequently
incorporated in autophagosomes by interacting with LC3-
associated phagophores (Fig. 3). The expanded polyQ tract
could alter the functional HTT-UKL1-p62 cargo-recognition
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complex and cause the observed malfunction of macroau-
tophagy in HD (Martinez-Vicente et al. 2010). This view is
supported by experiments with HD mice, in which a
deletion in the polyQ tract in full-length HTT enhanced
neuronal autophagy (Zheng et al. 2010). Finally, degrada-
tion of mutant but not wtHTT through selective autophagy
was shown to decrease in cells (Fu et al. 2017), substan-
tiating the relevance of this specific cellular protein
degradation process in pathogenesis.
mTOR signalling
The mechanistic target of rapamycin (mTOR) is a serine-
threonine kinase that regulates growth and metabolism of
cells by activation or deactivation of protein translation
(Laplante and Sabatini 2012). The mTOR protein assembles
into two protein complexes, mTORC1 and mTORC2, which
differ in their protein compositions and cellular activities
(Saxton and Sabatini 2017). In the brain, mTORC1 controls
Fig. 3 A graphic summary of the abnormal interactions between full-length mutant huntingtin (mHTT) and proteins involved in various cellular
processes. (a and b) Initiation of autophagy. (c and d) Mechanistic target of rapamycin (mTOR) signalling. (e and f) Vesicle transport along
microtubuli. (g) Fission of mitochondria. (h) Transport of mitochondria along microtubules. (i) Palmitoylation of synaptic proteins. (j) Regulation of
gene transcription.
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mitochondrial biogenesis and lipid homeostasis (Cunning-
ham et al. 2007; Peterson et al. 2011). Additionally, it
promotes myelination, axon growth and regeneration (Kim
et al. 2012), making its continuous activity indispensable for
neuronal function and survival. Recent results with HD
knock-in and transgenic mice revealed that mTORC1 activity
is significantly impaired in neuronal cells (Lee et al. 2015).
In addition, expression of Rhes, a RAS-like mTOR inducer,
which is enriched in the striatum (Subramaniam et al. 2009),
was reduced in HD patient and mouse brains and exogenous
expression of this protein alleviated motor symptoms and
improved brain pathology in HD mice. All this evidence
suggests that impairment of mTOR activity in neurons may
drive development of HD (Fig. 3). Strikingly, independent
investigations demonstrated that the GTPase Rhes binds
more strongly to mutant than to wild-type full-length HTT
(Subramaniam et al. 2009), suggesting that the observed
impairment of mTOR activity in HD brains could be caused
by this perturbed interaction. However, a potentially disease-
relevant mTOR-independent function of Rhes has also been
described later: Via an interaction with the autophagy
regulator Beclin-1, Rhes robustly activated autophagy in
PC12 cells (Mealer et al. 2014). However, this activity was
blocked by co-expression of mHTT, suggesting that an
inhibition of the abnormally strong interaction between
mHTT and Rhes with therapeutic molecules might reactivate
mTOR signalling and, independently of this, also lead to an
activation of autophagy in HD neurons.
Palmitoylation
The reversible post-translational modification of cysteine
residues by palmitate critically regulates the localization and
cellular function of a large number of human proteins (el-
Husseini Ael and Bredt 2002; Huang and El-Husseini 2005).
Among other functions, it controls protein trafficking along
axons or the release of neurotransmitters in synapses (Brigidi
et al. 2014). Previous research has demonstrated that full-
length wtHTT gets palmitoylated in cortical neurons (Yanai
et al. 2006) and interacts directly with the palmitoyl
transferase huntingtin interacting protein 14 (HIP14)
(DHHC17). In turn, HIP14 interacts with many important
synaptic proteins such as synaptosomal nerve-associated
protein 25 or PSD-95 (Fig. 3) and thereby influences synapse
function and neurotransmission (Huang et al. 2004). Mech-
anistic studies have shown that binding of wtHTT to HIP14
activates its palmitoyl transferase activity and promotes the
palmitoylation of synaptosomal nerve-associated protein 25
and other synaptic proteins (Huang et al. 2011). This
suggests that wtHTT functions as a palmitoylation facilitator
for synaptic proteins and thereby regulates synapse function.
In cells expressing mHTT, the palmitoylation of synaptic
proteins was found to be reduced (Huang et al. 2011). The
expanded polyQ tract appears to perturb the functional
interaction with HIP14, leading to a decrease in its enzymatic
activity. This is supported by yeast two-hybrid interaction
studies, in which the binding of mHTT to HIP14 is decreased
in comparison to the wild-type protein (Singaraja et al.
2002). Impairment of HIP14 palmitoyl transferase activity in
specific neurons may contribute to the development of
disease symptoms. The potential relevance of a loss of HIP14
function in HD is also supported by genetic knock-out
studies in mice, indicating that mice deficient in HIP14 and
HIP14L (a HIP14 related protein) both recapitulate important
features of HD (Singaraja et al. 2011; Sutton et al. 2013).
Mitochondrial fission and mitophagy
Cycles of mitochondrial fusion and fission are essential for
neuronal function. Imbalance of these opposing processes
initiates neurodegeneration (Knott et al. 2008). Evidence was
presented that the GTPase dynamin-related protein-1
(DRP1), which binds to mitochondria and controls mito-
chondrial fission, interacts more strongly with mutant than
with wild-type full-length HTT in co-immunoprecipitation
experiments (Song et al. 2011). In cells expressing mHTT, a
significant increase in DRP1-mediated fission activity was
observed (Fig. 3), indicating that the mutation affects the
interaction with functional consequences (Song et al. 2011).
As it may trigger downstream apoptosis and cell death, the
fragmentation of mitochondria is tightly controlled in
neuronal cells (Costa et al. 2010). Thus, mHTT-induced
mitochondrial fission may lead to neuronal dysfunction and
toxicity in HD patient brains. This hypothesis is supported by
investigations in zQ175 HD mice, which showed that
inhibition of DRP1 hyperactivity with a peptide reduces
behavioural deficits (Zhao et al. 2018). An abnormal
interaction between mHTT and DRP1 was also detected in
postmortem brains of HD patients (Shirendeb et al. 2012).
The relevance of mitochondrial dysfunction in HD is
substantiated further by recent findings that mHTT promotes
the recruitment of the AAA ATPase valosin-containing
protein (VCP) to mitochondria and that this translocation is
associated with enhanced mitophagy in models of HD (Guo
et al. 2016). Hence, an abnormal mHTT–VCP interaction at
the surface of mitochondria may also contribute to the
induction of cell death in brains of HD patients. The disease
relevance of these results is supported by the fact that a
peptide inhibitor which blocks the interaction between VCP
and mHTT reduces the behavioural and neuropathological
phenotypes in HD mice.
Gene transcription
Numerous studies have reported that wtHTT binds to
transcription factors (Steffan et al. 2000; Valor 2015)
suggesting that it functions as gene expression regulator in
mammalian cells. This involves the binding to important
transcriptional activators such as specificity protein 1 (SP1)
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(Dunah et al. 2002) and neurogenic differentiation factor 1
(Marcora et al. 2003) to transcriptional repressors such as
RE1-silencing transcription factor/neuron-restrictive silencer
factor (Zuccato et al. 2003) or to components of the core
transcription apparatus such as transcription factor II D or
transcription factor II F (Zhai et al. 2005). Because wtHTT
interacts with many partners belonging to the transcription
machinery in the nucleus, it is regarded as a relevant
influence on the expression of a wide range of target genes
(Fig. 3). This critical molecular function is perturbed in cells
upon expression of mHTT with an expanded polyQ tract: in
co-immunoprecipitation experiments, for instance, mHTT
was shown to bind more strongly to the transcription
activator SP1 than the wild-type protein (Dunah et al.
2002). More detailed studies revealed that mHTT specifically
repressed SP1-dependent transcription in cell-free assays
(Zhai et al. 2005), underlining the perturbatory role of
aberrant interactions between mHTT and transcription fac-
tors on gene expression. The disease relevance of a stronger
mHTT-SP1 binding was supported by an independent study
demonstrating that the expression of the metabolic enzyme
cystathione c-lyase is significantly down-regulated in HD
models at the transcript level and that this effect is mediated
by an abnormal interaction between mHTT and SP1 (Paul
et al. 2014). Consistent with the notion of a loss of
cystathione c-lyase as a pathogenic mechanism, supplemen-
tation with cysteine reversed abnormalities in HD tissue
cultures and mouse models (Sbodio et al. 2016). Interfering
with the enhanced binding of mHTT to SP1 may be a valid
therapeutic strategy for HD.
More recent investigations indicate that the peroxisome
proliferator-activated receptor delta (PPAR-d) binds more
strongly to mHTT than to the wild-type protein and that
PPAR-d transactivation is repressed by this abnormal PPI
(Dickey et al. 2016). PPAR-d is a ligand-activated transcrip-
tion factor that belongs to a nuclear hormone receptor family.
It serves as a lipid sensor that is activated in response to
increasing energy requirements and regulates mitochondrial
energy production in the skeletal muscles and brain (Berger
and Moller 2002). The abnormal interaction might contribute
to the mitochondrial dysfunction observed in HD patient
brains (Vonsattel et al. 2011). This view is supported by
findings in HD mouse models that PPAR-d activation by
bexarotene restores mitochondrial function and promotes
neuroprotection (Dickey et al. 2017). The dysfunction of
mitochondria in HD is linked to transcriptional dysregulation
of PGC-1a (peroxisome proliferator-activated receptor
gamma co-activaotor-1 alpha) that coordinates the transcrip-
tional profiles responsible for mitochondrial biogenesis
(Finck and Kelly 2006). The importance of PGC-1a in HD
is underscored by the observation that its levels are decreased
in mHTT-expressing striatal cells and that its overexpression
is sufficient to rescue motor dysfunction and to reduce
neurodegeneration in HD mice (Cui et al. 2006). Thus,
abnormal interactions between PPAR-d or its related proteins
PPAR-a and PPAR-c (Jin et al. 2012; Chandra et al. 2016)
with mHTT and PGC-1a may be responsible for mitochon-
drial dysfunction as well as the reduced production of ATP
observed in HD patients and model systems (Intihar et al.
2019).
Abnormal interactions among mHTT fragments and
with other polyQ-containing proteins
The HTTex1 fragment contains the expandable polyQ stretch
which is preceded by 17 amino acids (N17) and followed by
a proline-rich domain. It is conformationally highly flexible
and therefore considered an intrinsically disordered protein
(Kim et al. 2009; Giorgini 2013; Baias et al. 2017).
Homotypic interaction of HTTex1 fragments leads to the
spontaneous self-assembly of HTTex1 fibrils in aqueous
solution (Scherzinger et al. 1997; Scherzinger et al. 1999;
Wanker et al. 1999; Sahoo et al. 2014). The expansion of the
polyglutamine stretch greatly facilitates this process and
leads to the rapid formation of insoluble amyloidogenic
fibrillar aggregates with cross-b-sheet architecture (Scher-
zinger et al. 1999; Sahoo et al. 2014). Fibril formation
follows a nucleated growth mechanism (Bhattacharyya et al.
2005; Wagner et al. 2018). The initial association between
HTTex1 molecules is believed to be mediated by coiled-coil
interactions of multiple N17 domains (Thakur et al. 2009;
Jayaraman et al. 2012). This association may bring polyQ
stretches of individual molecules into close proximity,
enhancing the polyQ–polyQ interaction and facilitating the
transition to a b-hairpin conformation (Hoop et al. 2016;
Kang et al. 2017b). These initial conformational changes
(primary nucleation) are slow and rare to occur and therefore
manifest in a lag phase, when looking at the aggregation
process from a kinetic point of view. Then, fibril formation
proceeds to a rapid elongation phase in which additional
HTTex1 monomers are recruited to the primary nucleus and
adapt a b-hairpin conformation (Wagner et al. 2018). Within
the mature fibre, multiple molecules with a b-hairpin
conformation are stacked atop each other, stabilized by
intra- and intermolecular hydrogen bonds, thereby forming
tightly interconnected b-sheets (Hoop et al. 2016).
Pathogenic HTTex1 fragments also interact in cells and
efficiently form fibrillar aggregates in vivo (Davies et al.
1997; DiFiglia et al. 1997; Scherzinger et al. 1997),
demonstrating that abnormal homotypic mHTT interaction
leads to the formation of aggregates which may perturb
cellular functions and thereby drive pathogenesis. Interac-
tions between pathogenic and non-pathogenic HTTex1
fragments have been detected in cell-free assays, leading to
the co-assembly of mixed HTTex1 fibrils with high stability
(Busch et al. 2003). Such structures may also form in vivo,
suggesting that loss of normal HTT function through
incorporation of wild-type protein molecules into mutant
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HTT fibrils may contribute to HD development. In addition,
the disease relevance of fibrillar mutant HTTex1 aggregates
is supported by cell-based assays indicating that such
structures are rapidly taken up into cells (Ren et al. 2009;
Holmes et al. 2013), possibly inducing toxicity. Furthermore,
there is accumulating evidence that HTTex1 fibrils can self-
propagate and efficiently spread from cell to cell (Costanzo
et al. 2013; Babcock and Ganetzky 2015; Jeon et al. 2016;
Masnata et al. 2019), suggesting that the active uptake and
release of mHTT fibrils are important elements of pathogen-
esis and disease progression. The discovery that mutant
HTTex1 seeding activity in fly neurons correlates with
neurotoxicity and reduced survival supports this view (Ast
et al. 2018).
A number of studies have shown that other proteins with
glutamine-rich domains can interact with mHTT fragments
and might be at the root of cellular toxicity by being
sequestered into HTT aggregates. These proteins are mainly
transcription factors such as TATA-binding protein (TBP)
and CREB-binding protein (CBP). The TBP that contains a
polymorphic polyQ domain in the N-terminus is recruited
into aggregates formed of N-terminal mHTT fragments
in vitro and in cells and is also present in HTT aggregates
from post-mortem HD brains (Huang et al. 1998; Schaffar
et al. 2004). The nuclear transcriptional coactivator CBP,
which contains a glutamine-rich C-terminus, interacts with
mHTTex1 in vitro (Steffan et al. 2000) as well as with N-
terminal mHTT (Nucifora et al. 2001). Immunoprecipitation
experiments with N2a cells confirmed a direct interaction
between CBP and an mHTT fragment (Nucifora et al. 2001).
The interactions of both CBP and TBP with mHTT are
highly dependent on the polyQ domains, as they do not take
place when the polyQ regions are deleted in the two proteins
(Nucifora et al. 2001; Schaffar et al. 2004). CBP localizes to
intranuclear inclusions in striatal sections of R6/2 transgenic
HTT mice (Steffan et al. 2000), cortical neurons of Htt-
N171-82Q transgenic mice and human post-mortem cortex
(Kazantsev et al. 1999). These studies provide strong
evidence that CBP and TBP are sequestered into mHTT
aggregates leading to decreased CBP and TBP-mediated
transcription (Nucifora et al. 2001; Schaffar et al. 2004). The
resulting cellular toxicity could be compensated by the
overexpression of TBP or CBP respectively (Nucifora et al.
2001; Schaffar et al. 2004). Another glutamine-rich tran-
scription factor, SP1, has been shown to directly interact with
wild-type and mutant HTTex1 as well as other N-terminal
HTT fragments (Li et al. 2002). The polyQ expansion
enhances the interaction of mHTT and the SP1 protein and
thereby reduces its transcriptional activity in cultured cells. In
R6/2 mice, which express mHTTex1, SP1 interacts with
soluble mHTT, but not with mHTT aggregates (Li et al.
2002). Finally, studies in yeast showed a co-localization of
mHTT fragments with several polyQ-rich proteins, such as
Cyc8, Snf5 (Duennwald et al. 2006) or Gts1p, a direct
interactor (Ripaud et al. 2014), supporting a role of abnormal
polyQ–protein interactions in disease.
Abnormal interactions between mHTT aggregates
and cellular proteins – formation of inclusion
bodies
The deposition of insoluble fibrillar mHTT aggregates in
neuronal intranuclear inclusions (NIIs) in the cortex and
striatum is a pathological hallmark of HD patient brains
(DiFiglia et al. 1997). Also, NIIs with fibrillar mHTTex1
aggregates were detected in the brains of HD transgenic mice
prior to the development of neuronal symptoms (Davies et al.
1997; Scherzinger et al. 1997). The formation of such
structures in neurons is therefore associated with disease
development or might even drive the pathogenic process.
However, experimental evidence from cell culture studies
also pointed to inclusion body formation as reducing levels
of soluble mHTT in the cytoplasm and decreasing the risk of
neuronal death. This suggests that the formation of such
structures in neurons might be a homeostatic coping
mechanism rather than a process that drives pathogenesis
(Arrasate et al. 2004; Miller et al. 2010).
Histological investigation of HD patient and mouse brains
revealed that NIIs are complex structures that contain a large
number of cellular proteins besides insoluble mHTT aggre-
gates. These include, for example, ubiquitin, molecular
chaperones or components of the ubiquitin-proteasome
system (Davies et al. 1997; DiFiglia et al. 1997). As a
consequence, recruitment of important cellular proteins into
inclusion bodies and abnormal interactions between mHTT
aggregates and components of the protein quality control
machinery have to be regarded as linked to each other and
possibly to the progressive neuronal dysfunction observed in
HD transgenic mice.
Cell-based studies confirmed that N-terminal mHTTex1
fragments with pathogenic polyQ tracts rapidly self-assemble
into insoluble, fibrillar protein aggregates and sequester
quality control proteins such as ubiquitin, chaperones or
components of the 26S proteasome into inclusion bodies
(Waelter et al. 2001). Dramatic ultrastructural changes in
cells with mHTTex1 inclusion bodies, such as the disruption
of the nuclear and ER membranes, have been established
formerly (Waelter et al. 2001). Recent high-resolution cryo-
EM studies in primary neurons and immortalized cells
confirm these initial observations (Fig. 2), indicating that
complex networks of mHTTex1 fibrils in inclusion bodies
lead to aberrant interactions with endomembranes and impair
the ER organization (Bauerlein et al. 2017).
Mass spectrometry (MS)-based quantitative proteomics of
neuronal inclusions with mHTTex1 aggregates have detected
many other proteins to be enriched, in addition to chaperones
and components of the ubiquitin-proteasome system, includ-
ing RNA-binding proteins, myelin components and proteins
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involved in neuronal plasticity (Hosp et al. 2017). This
extends the range of neuronal functions impaired by protein
sequestration into NIIs in the disease. A similar result had
been obtained when the composition of insoluble mHTT
inclusions formed in a neuroblastoma cell line was assessed
with quantitative mass spectrometry-based proteomics meth-
ods (Kim et al. 2016). Interestingly, these studies also
demonstrated that smaller, soluble mHTTex1 assemblies
have more abnormal interactions with cellular proteins than
fibrillar aggregates deposited in inclusion bodies. This
indicates that the binding of chaperones and proteins of the
quality control machinery to mHTTex1 fibrils in inclusion
bodies, at least partly, results in surface shielding, while the
cellular interactions of diffusible mHTT species remain
manyfold. They are thought to perturb multiple critical
processes such as ribosome biogenesis, translation, transcrip-
tion and vesicle transport (Kim et al. 2016).
Bioinformatic analysis revealed that predominantly unstruc-
tured low complexity regions (LCRs) associate with soluble or
insoluble mHTTex1 assemblies (Kim et al. 2016). Such
domains have an important physiological role in RNA-binding
proteins and recently have been found to mediate their
reversible functional polymerization into hydrogels, which
leads to an increased concentration of binding partners in cells
and is crucial for the formation of RNA granules (Han et al.
2012; Murakami et al. 2015). However, under conditions of
prolonged stress or when mutated, the LCR-containing
proteins can undergo a phase transition, leading to the
formation of potentially toxic fibrillar aggregates (Mompean
and Laurents 2017). Thus, it seems reasonable to speculate
that the fibrillogenesis of RNA-binding proteins with LCRs
gets stimulated by abnormal interactions with aggregated
mHTT species. Experimental evidence that RNA-binding
proteins with LCRs such as FUS (fused in sarcoma) co-
aggregate with mHTTex1 fragments into SDS-stable, high-
molecular weight aggregates was provided previously (Wear
et al. 2015). However, a liquid-to-solid phase transition for
polyQ-containing HTTex1 proteins has been recently
described, indicating that also the mHTT aggregation process
in neurons may involve liquid-like assemblies prior to the
formation of fibrillar structures (Peskett et al. 2018).
Future perspectives
While the scientific community agrees that the expanded
polyQ tract in HTT, directly or indirectly, perturbs multiple
PPIs in cells and various other disease models, it remains
debated which of these alterations are detectable under
endogenous conditions in patient neurons and at what point
they occur in the pathogenic process. It will be of critical
importance to determine whether changes in PPIs that can be
detected and quantified in patient cells eventually contribute
to pathogenesis. In HD, selective striatal neuronal loss is
observed in patient brains (Ross and Tabrizi 2011). Mutant
and wtHTT, however, are expressed uniformly throughout
the brain and the rest of the body. Striatal selectivity of HD
may be explained by binding of mHTT to proteins that are
predominantly expressed in this brain region such as the
small guanine nucleotide-binding protein Rhes, which,
together with proteins such as ACBD3 (Sbodio et al.
2013), mediates mHTT toxicity in various model systems
(Subramaniam et al. 2009). Experimental evidence was
presented that Rhes binds more strongly to mutant than to
wtHTT in knock-in striatal neuronal cells (Subramaniam
et al. 2009). Whether an abnormal mHTT : Rhes interaction
in brains of HD patients or knock-in mice is responsible for
the observed selective striatal vulnerability, however,
remains unclear. Further specific in vivo studies with Rhes
mutants, which weakly bind mHTT, are necessary to
elucidate whether an abnormal association between Rhes
and mHTT is indeed responsible for the selective destruction
of the corpus striatum in HD.
In systematic future studies perturbed PPIs need to be
prioritized in terms of their relevance to disease and
experimental strategies to rescue such interactions with
therapeutic molecules in model systems need to be devel-
oped. Complex disease phenotypes triggered by multiple
changes in the interactome network might only be treated
successfully with a polypharmacological approach that
involves more than one therapeutic molecule to target and
correct the perturbed network. In the context of HD, a
successful therapeutic strategy could require the targeting of
abnormal cellular interactions of full-length a-helical mHTT
as well as the targeting of the interactions of mHTTex1 and
b-sheet-rich mHTT aggregates. At the same time, an
inhibition of homotypic interactions between mHTT frag-
ments, leading to the assembly of stable, self-propagating
fibrillar structures, may be crucial for therapeutic success.
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